Success Metrics

Active Trials
3(50%)

Phase Distribution

Ph phase_4
2
33%
Ph phase_3
1
17%
Ph phase_2
1
17%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Enrolling by invitation3
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 12 (33.3%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 42 (33.3%)

Trials by Status

recruiting233%
active_not_recruiting117%
enrolling_by_invitation350%

Recent Activity

3 active trials
Showing 5 of 6
enrolling_by_invitationphase_2

Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease

NCT07372781
recruitingphase_4

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

NCT07213765
recruitingphase_4

Short-term Bactericidal Effect of Contezolid in MAC-PD

NCT07084402
active_not_recruitingphase_3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

NCT06081361
enrolling_by_invitationphase_1

Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis

NCT06811012
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07372781Phase 2

Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease

Enrolling By Invitation
NCT07213765Phase 4

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Recruiting
NCT07084402Phase 4

Short-term Bactericidal Effect of Contezolid in MAC-PD

Recruiting
NCT06081361Phase 3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active Not Recruiting
NCT06811012Phase 1

Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis

Enrolling By Invitation
NCT06811025Phase 1

Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

Enrolling By Invitation

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6